BioSpace News Archive

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors has elected Ms. Tracey C. Doi to serve as a director.

Kraig Biocraft Laboratories, Inc., the leading developer of spider silk-based fibers, announces the opening of a new spider silk production factory located in Vietnam.

OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapies, announced the appointment of Evan Ballantyne as Chief Financial Officer.

Helius Medical Technologies, Inc. announced that it has received Breakthrough Designation from the U.S. Food and Drug Administration for its PoNS™ device with the proposed indication for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from stroke, to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over.

AzurRx BioPharma, Inc., a company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced the World Health Organization has published “adrulipase alfa” as the proposed International Nonproprietary Name for MS1819.

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, reported its unaudited financial results for the second quarter of the year and recent business highlights.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced six data presentations at the American Academy of Orthopaedic Surgeons 2021 Annual Meeting scheduled to be held on August 31 to September 3 in San Diego.

EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Cybin Inc. today announced that it has filed a new non-provisional patent application in support of its ongoing drug candidate programs.

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended June 30, 2021.